New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19.
Mult Scler Relat Disord
; 57: 103321, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-35158439
ABSTRACT
We report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These patients had been stable for a median period of six years, with no evidence of disease activity and no change in their medication. After a median of 13 days (7 to 25 days) from vaccination, they developed a new relapse with increased disability and new lesions on magnetic resonance imaging. Although this association may be rare, it might be an adverse event of AZD1222.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neuromielite Óptica
/
COVID-19
/
Esclerose Múltipla
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article